drugset / Trial / NCT01964937
Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Phase 1
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
EuroVacc Foundation · collabGlobal Solutions for Infectious Diseases · collabIPPOX Foundation · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study will evaluate the safety and immune response to five different combinations of three HIV vaccines in healthy, HIV-uninfected adults.
Timeline
- Start
- —
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AIDSVAX B/E | Vaccine | 600 ug | Intramuscular |
| Subject | AIDSVAX B/E | Vaccine | 1 ml | Intramuscular |
| Subject | DNA-HIV-PT123 | Vaccine | 4 mg | Intramuscular |
| Subject | NYVAC-HIV-PT1 | Vaccine | 5e+06 unknown | Intramuscular |
| Subject | NYVAC-HIV-PT1 | Vaccine | 1.2e+08 unknown | Intramuscular |
| Subject | NYVAC-HIV-PT4 | Vaccine | 5e+06 unknown | Intramuscular |
| Subject | NYVAC-HIV-PT4 | Vaccine | 1.1e+07 unknown | Intramuscular |